Welcome to our dedicated page for Coherus BioSciences news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus BioSciences stock.
Coherus BioSciences, Inc. (NASDAQ: CHRS) is a leading commercial-stage biopharmaceutical company dedicated to improving patient access to high-quality, life-changing biologic medicines. Established in 2010 and headquartered in the San Francisco Bay Area, Coherus specializes in developing biosimilars and innovative immuno-oncology therapies to treat various chronic and life-threatening diseases.
Coherus' core business revolves around providing biosimilar therapeutics that are designed to replace existing branded biologics, thereby reducing healthcare costs. The company's biosimilar portfolio includes FDA-approved products like UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), which is set to launch in the US in 2023. These products help manage conditions such as cancer and autoimmune diseases, expanding patient access to essential treatments.
Recently, Coherus completed the divestiture of its ophthalmology franchise, CIMERLI®, to Sandoz, Inc. for $170 million. This move allows Coherus to focus more intently on its immuno-oncology pipeline, which includes the promotion of LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor approved for nasopharyngeal carcinoma. The company's strategy includes advancing its novel immuno-oncology candidates like CHS-114 and CHS-1000, which are in various stages of clinical development targeting solid tumors.
Financially, Coherus is leveraging the revenue from its biosimilar products to fund its immuno-oncology research and development. The company collaborates with global pharmaceutical partners across Europe, Asia, and Latin America, enhancing its market presence and resource capabilities.
Key updates include the successful preclinical data presentation for CHS-1000 at the 2024 AACR Annual Meeting, showcasing its potential to reverse immunosuppression in the tumor microenvironment. Moreover, the Cancer Research Institute (CRI) has selected LOQTORZI for combination studies to explore its efficacy in drug-resistant cancers, further solidifying Coherus' commitment to pioneering cancer therapy advancements.
Led by a team of seasoned industry veterans, Coherus BioSciences aims to become a global leader in the biosimilar and immuno-oncology markets, continually striving to develop therapies that improve patient outcomes and broaden access to high-quality medical treatments.
On April 27, 2023, Coherus BioSciences (Nasdaq: CHRS) and Junshi Biosciences announced that data from four pivotal clinical studies of toripalimab will be presented at the ASCO Annual Meeting from June 2-6, 2023. Key presentations include final overall survival analyses from phase 3 studies for nasopharyngeal carcinoma and non-small cell lung cancer, and interim analyses for resectable stage cancers. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for advanced recurrent nasopharyngeal carcinoma. This demonstrates the potential of toripalimab, an anti-PD-1 monoclonal antibody, in treating multiple cancer types, with ongoing studies covering over 15 indications globally.
FAQ
What is the current stock price of Coherus BioSciences (CHRS)?
What is the market cap of Coherus BioSciences (CHRS)?
What does Coherus BioSciences specialize in?
Where is Coherus BioSciences headquartered?
What are some of Coherus' FDA-approved products?
What recent transactions has Coherus BioSciences completed?
How does Coherus BioSciences fund its immuno-oncology research?
What is the significance of Coherus' partnership with the Cancer Research Institute?
Which markets do Coherus' partnerships cover?
What recent achievements has Coherus made in its clinical pipeline?
Who are the key figures in Coherus BioSciences' leadership?
What is the focus of Coherus' CHS-114 clinical trials?
